Every broad-neutralizing antibody (bNAb) combination in HIV development has stumbled on the same practical obstacle: resistance screening. Patients require pre-treatment genotyping to confirm viral susceptibility before a regimen can even begin, a step that shrinks the eligible population and complicates rollout in lower-resource settings. TaiMed Biologics is betting its entire Phase 2b program on eliminating that requirement — and with enrollment now closed ahead of schedule, the clinical stress test of that premise is underway.
The Phase 2b study of TMB-365/380 — a dual-bNAb combination dosed every two months — completed Last Patient In ahead of the planned timeline, with an interim analysis expected before year-end 2026. The speed of enrollment is itself informative: site investigators did not struggle to recruit, which in the long-acting HIV space often reflects genuine patient and physician appetite for less-frequent dosing alternatives to the current standard-bearers, ViiV’s cabotegravir/rilpivirine and Gilead’s lenacapavir-based regimens. The early viral suppression signal through the first two doses is described as consistent with internal expectations, though that language is deliberately vague at this stage and the interim data will be the first real reckoning.
The design ambition here is substantial. Most bNAb programs — including earlier iterations from Rockefeller University and the NIH — required susceptibility confirmation because not all circulating HIV strains are neutralized equally across antibody classes. If TMB-365/380 genuinely sustains viral suppression without that pre-screening step across a heterogeneous enrolled population, it rewrites the access calculus for bNAb-based maintenance therapy. The company intends to file for Breakthrough Therapy Designation contingent on continued positive interim outcomes, a regulatory move that would accelerate FDA dialogue and signal confidence in the dataset’s trajectory. Peak sales projections of $3–4 billion annually reflect an assumption of broad clinical deployment, not a niche-rescued salvage therapy position.
The single number to watch in the year-end interim readout is the viral suppression rate at 24 weeks in participants who were not pre-screened for susceptibility — if that figure holds above 90%, the no-screening thesis survives scrutiny and TaiMed’s partnering conversations shift from exploratory to urgent.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
